Clinical trials
Relapsed Peripheral T-Cell Lymphoma clinical trials
Below are recruiting relapsed peripheral t-cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 93 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06160843RecruitingPhase 2
Pembrolizumab and olaparib for relapsed peripheral T-cell lymphoma
This trial tests whether combining two targeted drugs, pembrolizumab and olaparib, can help people with peripheral T-cell lymphoma that has come back or not responded to previous treatment. The goal is to find a new option for this type of cancer.
SingaporeAges 21–99 - NCT06176027RecruitingPhase 1/Phase 2
New drug combo for returning AITL lymphoma
This trial tests a new combination of drugs (azacytidine plus CAOLD) for people with a specific type of T-cell lymphoma called AITL that has come back or not responded to previous treatment. The goal is to see if this treatment can work better than current options.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06244368RecruitingPhase 2
Chemo combo for relapsed aggressive lymphoma
This trial tests a combination of chemotherapy drugs (GVM, with or without rituximab) for people whose aggressive non-Hodgkin lymphoma has returned or not responded to standard treatment. It aims to find a new option that might work when others have stopped working.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT06252675RecruitingPhase 2
Glofitamab and pirtobrutinib for relapsed mantle cell lymphoma
This study tests a combination of two drugs—glofitamab (given as an infusion) and pirtobrutinib (a pill)—for people with mantle cell lymphoma that has come back or not responded to previous treatment. The goal is to see if the combo works better than either drug alone.
Davis, CaliforniaAges 18 years+ - NCT06468267RecruitingPhase 2
Lower-intensity transplant with thiotepa combo for relapsed T-cell lymphoma
This study tests a stronger but safer chemo preparation before a stem cell transplant for people with T-cell lymphoma that has returned or not responded to treatment.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06486051RecruitingPhase 2
CAR T-cell therapy for relapsed large B-cell lymphoma
This trial tests a new CAR T-cell treatment (WZTL-002) for adults whose large B-cell lymphoma has come back or not responded to previous therapy. It aims to see if this treatment can help when standard treatments have stopped working.
Christchurch, Christchurch CentralAges 18–75 - NCT06508463RecruitingPhase 1
Viral therapy for peripheral T-cell lymphoma
This study tests an experimental virus therapy given through a vein for people with a type of lymphoma called peripheral T-cell lymphoma that has come back or not responded to treatment. The virus is designed to infect and destroy cancer cells. Some patients may also receive another drug called cemiplimab as part of a combination group.
Scottsdale, ArizonaAges 18 years+ - NCT06519526RecruitingPhase 2
Study of two drugs for relapsed peripheral T-cell lymphoma
This study tests two new drugs (SHR-0302 and SHR-2554) for people with a type of lymphoma (peripheral T-cell lymphoma) that has come back or not responded to prior treatment. The goal is to see if the combination can help control the cancer.
ShanghaiAges 18–70 - NCT06547528RecruitingPhase 1
Testing ONO-4685 for T cell lymphoma and CLL/SLL
This trial tests a new drug, ONO-4685, for people with certain types of T cell lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) that has not responded to standard treatments or cannot tolerate them. The goal is to see if the drug is safe and tolerable.
Nagoya, Aichi-kenAges 18 years+ - NCT06561048RecruitingPhase 3
Soquelitinib vs standard care for relapsed or refractory T-cell lymphoma
This trial compares a new drug, soquelitinib, with standard treatments for peripheral T-cell lymphoma that has come back or not responded to previous therapy. It may help people who have had one to three prior treatments and are looking for a new option.
Duarte, CaliforniaAges 18 years+ - NCT06561074RecruitingPhase 2
Study of calaspargase, decitabine, and venetoclax for young T-cell cancer
This trial tests a combination of three drugs (calaspargase, decitabine, and venetoclax) for children, teens, and young adults with T-cell leukemia or lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help destroy cancer cells.
Houston, TexasAges 1 month–21 years - NCT06696846RecruitingPhase 1
CAR-NK cell therapy for T cell lymphoma and acute myeloid leukemia
This trial tests an immune cell treatment (CAR-NK cells) targeting a protein called CD70 found on cancer cells. It's for people with T cell lymphoma or acute myeloid leukemia that has come back or not responded to other treatments.
Hangzhou, ZhejiangAges 18–75 - NCT05833724RecruitingPhase 2
Chidamide for relapsed or resistant peripheral T-cell lymphoma
This trial tests chidamide (a targeted medicine that affects how cells manage gene activity) in people whose peripheral T-cell lymphoma has come back or did not respond to treatment. It may help shrink measurable tumors and control the disease after prior therapies.
Kaohsiung CityAges 20–75 - NCT06712810RecruitingPhase 1
Q702 for blood cancers and histiocytic disorders
This study tests an experimental pill called Q702 for people with certain blood cancers and related disorders (like histiocytoses, myelofibrosis, and lymphomas) that have not responded to standard treatments. It aims to see if Q702 is safe and effective.
Scottsdale, ArizonaAges 18 years+ - NCT06733441RecruitingPhase 1
Study of TLN-254 for T-cell lymphoma that has come back
This study tests a new drug called TLN-254 for people with T-cell lymphoma that has not gotten better with or has come back after other treatments. The drug is given by mouth and aims to shrink the lymphoma or stop it from growing.
Stanford, CaliforniaAges 18 years+ - NCT06756308RecruitingPhase 2
Enasidenib for IDH2-mutated T-cell lymphoma
This trial tests a drug called enasidenib for people with a rare type of T-cell lymphoma (AITL) that has a specific IDH2 gene mutation. The goal is to see if enasidenib can shrink tumors or slow the disease.
Boston, MassachusettsAges 18 years+ - NCT06776952RecruitingPhase 3
Study of XNW5004 for relapsed or refractory peripheral T-cell lymphoma
This study tests a new oral tablet called XNW5004 for people with peripheral T-cell lymphoma (a type of blood cancer) that has come back or not responded to prior treatments. The goal is to see if this drug can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 3 weeks–2 months - NCT06810778RecruitingPhase 1/Phase 2
Duvelisib plus venetoclax for relapsed PTCL
This study tests two oral drugs—duvelisib and venetoclax—to see if together they can help people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has not responded to at least two prior treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT06839053RecruitingPhase 2
Study of sonrotoclax, rituximab, and zanubrutinib for CLL, SLL, and MCL
This trial tests a combination of three drugs (sonrotoclax, rituximab, and zanubrutinib) for people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or mantle cell lymphoma. The goal is to see if the combination works better than current treatments.
Seattle, WashingtonAges 18 years+ - NCT06854159RecruitingPhase 2
Odronextamab for diffuse large B-cell lymphoma before and after CAR T therapy
This trial tests a drug called odronextamab for people with diffuse large B-cell lymphoma that has come back or not responded to at least two prior treatments. It aims to see if the drug can help before and after a type of immunotherapy called CAR T-cell therapy.
Sacramento, CaliforniaAges 18 years+ - NCT06855823RecruitingPhase 1/Phase 2
Study of golidocitinib plus pomalidomide for relapsed/refractory PTCL
This trial tests a combination of two drugs, golidocitinib and pomalidomide, for people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has come back or stopped responding to prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
Guangzhou, GuangdongAges 18–80 - NCT06909877RecruitingPhase 1/Phase 2
Study of HH2853 for relapsed or refractory peripheral T-cell lymphoma
This trial tests an experimental drug, HH2853, for people with certain types of T-cell lymphoma that have come back or not responded to prior treatments. It aims to see if the drug is safe and effective.
Chengdu, ChengduAges 18–75 - NCT06914037RecruitingPhase 1
CHT101 for CD70-positive blood cancers
This trial tests a new drug, CHT101, for people with certain blood cancers that have not responded to prior treatments. It is specifically for cancers that test positive for a protein called CD70.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT06925464RecruitingPhase 1/Phase 2
Modified immune cells for T-cell lymphoma
This trial tests a new treatment where your own immune cells are modified to find and attack CD7-positive T-cell lymphoma cells. It is for people whose lymphoma has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 14–70
Hear when a new Relapsed Peripheral T-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed peripheral t-cell lymphoma?
- Yes. Clin2 currently lists 93 recruiting relapsed peripheral t-cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed peripheral t-cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed peripheral t-cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory Peripheral T Cell Lymphoma
- Relapsed or Refractory Peripheral T Cell Lymphoma
- Peripheral T Cell Lymphoma
- Diffuse Large B Cell Lymphoma Relapsed
- Relapsed/Refractory B-cell Lymphoma
- Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Relapsed B-Cell Non-Hodgkin Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.